The report titled “Multiplex Assays Market Research Report – Forecast to 2023″ is a direct
appreciation by Market Research Future of the market potential of the Multiplex Assays
Market. The report intends to provide accurate and meaningful insights, both quantitative as
well as qualitative. It can be said with high confidence level, that this report will satisfy the
need for comprehensive insights needed to compete and beat other players in today’s
winner takes all market!
The Global Multiplex Assays Market is expected to reach an approximate CAGR of 7.2%
during the forecast period.
Get Premium Sample Copy @
https://www.marketresearchfuture.com/sample_request/6135
Global Multiplex Assays Market Key Players:
Luminex, Thermo Fisher Scientific, Illumina, Bio-Rad Laboratories, Qiagen, Abcam, Becton
Dickinson and Company, Merck, Agilent Technologies, Meso Scale Diagnostics, Randox
Laboratories, Quanterix, Bio-Techne, Olink, Seegene, and others.
Market Overview:
The increase in high-throughput screening tests in research and development for detection
of biomolecules of various diseases drives the market growth. Multiplex assays are used for
diagnosing various autoimmune diseases, infectious diseases, and chronic diseases such as
cancer and cardiovascular diseases. According to the National Institutes of Health (2012),
autoimmune diseases are most prevalent as compared to other diseases and 23.5 million
people in America suffer from autoimmune diseases, whereas 9 million people have cancer.
Thus, growing prevalence of such diseases and rise in government funding for the R&D
sector influence the growth in this market. The growing demand for rapid and precise
measurement of analyses, operational and labor cost reduction, rising use of multiplex
assays for diagnostic uses, and technological advancements are also the key factors for the
market to grow.
However, factors such as expensive multiplex assays, heavy capital investments, shortage
of skilled labor, and others are expected to restrict the market growth during the forecast
period.
Segmentation:
The global multiplex assays market is segmented on the basis of product and service, type,
technology, application, and end-user. The multiplex assays market, by product and service,
is sub-segmented into consumables, instruments, software and services, and others. On the
basis of type, the market is categorized into protein multiplex assays, nucleic acid multiplex
assays, cell-based multiplex assays, and others. Protein multiplex assays are further sub-
segmented into planar protein assays, bead-based protein assays, and others. Nucleic acid
multiplex assays are further sub-segmented into planar nucleic acid assays, bead-based
nucleic acid assays, and others. The technology segment includes flow cytometry,
fluorescence detection, luminescence, real-time multiplex PCR, and others. On the basis of
application, the market is categorized into research and development and clinical
diagnostics. The research & development segment includes drug discovery and development
and biomarker discovery and validation. The clinical diagnostics segment includes infectious
diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders,
metabolism and endocrinology disorders, and others. On the basis of end-user, the market
is segmented into pharmaceutical and biotechnology companies, hospitals and research
institutes, reference laboratories, and others. On the basis of region, the global multiplex
assays market is segmented into the Americas, Europe, Asia Pacific, and the Middle East
and Africa.
The Americas is sub-segmented into North America and South America. The North American
region is further segmented into the U.S. and Canada. The European region is divided into
two, namely, Western Europe and Eastern Europe. Western Europe is further classified into
Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific